According to the univariate analysis, the LIT group had lower birth body weight and weight at LZD medication; younger gestational ages; lower scores of Apgar at 1 min; longer durations of LZD treatment; more underlying conditions, such as late-onset sepsis (LOS), purulent meningitis, NEC, sepsis shock, respiratory failure, asphyxia, RDS, DIC, and ICH after LZD treatment, BPD; more mechanical ventilation; more use of meropenem; and lower baseline of PLT and albumin. The gene discussed is ALB; the disease is newborn respiratory distress syndrome.